N-Acetyl Selank Amidate is an enhanced derivative of Selank, a synthetic heptapeptide based on tuftsin with an added Pro-Gly-Pro sequence, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
Structure & Modifications
Base Selank Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
The N-Acetyl Amidate form includes N-terminal acetylation and C-terminal amidation for enhanced stability and blood-brain barrier penetration.
Mechanism of Action
GABAergic Modulation
Selank modulates GABA-A receptors, producing anxiolytic effects comparable to benzodiazepines but without tolerance, dependence, or cognitive impairment.
Multiple Neurotransmitter Systems
- Opioid system: Inhibits enkephalin-degrading enzymes
- Serotonergic and dopaminergic modulation
- BDNF elevation for neuroplasticity
Clinical Applications
- Generalized Anxiety Disorder: Approved in Russia for GAD
- Immune Modulation: Influences IL-6 and other cytokines
- Cognitive Enhancement: Combined anxiolytic and nootropic effects
Advantages Over Standard Selank
| Property | Selank | NA-Selank Amidate |
|---|---|---|
| Enzymatic stability | Moderate | High |
| BBB penetration | Good | Enhanced |
| Duration | Standard | Extended |
Regulatory Status
Selank was approved in Russia in 2009 for GAD. N-Acetyl Selank Amidate remains a research compound in most jurisdictions.